-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Zheng Zhongwei, director of the Science and Technology Development Center of the National Health Commission, stated at a press conference on the Joint Prevention and Control Mechanism of the State Council on the 7th that since the outbreak of the new crown epidemic, China has deployed inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines, and attenuated viruses.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Zheng Zhongwei introduced that 3 types of inactivated vaccines have been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
One adenovirus vector vaccine has been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
One recombinant protein vaccine has been approved by the State Food and Drug Administration for emergency use.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
One of the attenuated influenza virus vector vaccines is undergoing phase II clinical trials, and at the same time, it is coordinating to carry out phase III clinical trials abroad
.
.
Among the nucleic acid vaccines, one mRNA vaccine and one DNA vaccine have been approved by foreign phase III clinical trials, and related research is expected to be launched in the near future
.
.
Zheng Zhongwei, director of the Science and Technology Development Center of the National Health Commission, stated at a press conference on the Joint Prevention and Control Mechanism of the State Council on the 7th that since the outbreak of the new crown epidemic, China has deployed inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines, and attenuated viruses.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Zheng Zhongwei introduced that 3 types of inactivated vaccines have been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
One adenovirus vector vaccine has been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
One recombinant protein vaccine has been approved by the State Food and Drug Administration for emergency use.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
One of the attenuated influenza virus vector vaccines is undergoing phase II clinical trials, and at the same time, it is coordinating to carry out phase III clinical trials abroad
.
.
Among the nucleic acid vaccines, one mRNA vaccine and one DNA vaccine have been approved by foreign phase III clinical trials, and related research is expected to be launched in the near future
.
.
Zheng Zhongwei, director of the Science and Technology Development Center of the National Health Commission, stated at a press conference on the Joint Prevention and Control Mechanism of the State Council on the 7th that since the outbreak of the new crown epidemic, China has deployed inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines, and attenuated viruses.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Five technical routes for influenza virus vector vaccines are simultaneously advancing the research and development of new coronavirus vaccines
.
At present, China has achieved full coverage of clinical trials on 5 technical routes
.
Zheng Zhongwei introduced that 3 types of inactivated vaccines have been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
.
Two models have been approved by the State Drug Administration for emergency use, and phase III clinical trials are also being carried out abroad, and the overall progress is smooth
.
One adenovirus vector vaccine has been approved by the State Food and Drug Administration for conditional marketing, and large-scale vaccination is being carried out in China
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
.
Three models have been approved by the State Food and Drug Administration for Phase I and II clinical trials, and progress is generally smooth
.
One recombinant protein vaccine has been approved by the State Food and Drug Administration for emergency use.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
Its Phase III clinical trials abroad have collected enough cases and are undergoing mid-term analysis.
It is expected that it may apply for conditional marketing in the near future
.
In addition, there are 3 vaccines in China that are undergoing phase III clinical trials abroad, and 5 recombinant protein vaccines are undergoing phase I and phase II clinical trials.
The overall progress is smooth
.
One of the attenuated influenza virus vector vaccines is undergoing phase II clinical trials, and at the same time, it is coordinating to carry out phase III clinical trials abroad
.
.
Among the nucleic acid vaccines, one mRNA vaccine and one DNA vaccine have been approved by foreign phase III clinical trials, and related research is expected to be launched in the near future
.
.
